Abstract 1462P
Background
Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous histological group which amount 20-25% of RCC. nccRCC have limited therapeutic options due to their exclusion from phase III randomized trials. Therefore, the aim of this study was to investigate the efficacy of pembrolizumab- axitinib in chromophobe and papillary metastatic RCC patients enrolled in the I-RARE observational ongoing study (Meet-URO 23).
Methods
Baseline characteristics, outcome data including progression-free survival (PFS) and toxicities were retrospectively collected from nccRCC pts treated in 12 Italian referral centers adhering to the Meet-Uro group, from December 2020 to April 2022. Only patients with cromophobe and papillary histology were considered eligible.
Results
25 eligible patients received pembrolizumab-axitinib as first-line treatment. 11/25 (44%) patients had cromophobe histology whereas 14/25 (56%) were classified as papillary RCC. Characteristic of patients are reported in the table. The disease control rate was 86.3% (10/25 patients achieved stable disease and 9/25 patients obtained partial response: 5/9 papillary, 4/9 chromophobe). 2/25 (8%) patients were primary refractory. Median PFS was 10.8 months (95%CI 1.7-11.5). 7/25 (28%) patients interrupted the full treatment due to immune-related adverse events (irAEs) (G3 hepatitis (n=4), G3 hypophisitis (n=1), G2 pneumonia (n=1), G3 pancreatitis (n=1), whereas 2/25 (8%) patients interrupted axitinib only due to persistent G2 hand-foot syndrome or G2 hypertension. Table: 1462P
Characteristics of patients
| N (%) | |
| Median Age | 68 yrs |
| IMDC score | |
| Good | 4/25 (16) |
| Intermediate | 15/25(60) |
| Poor | 6/25(24) |
| Previous Nephrectomy | 15/25 (60) |
| ECOG PS | |
| 0 | 18/25 (72) |
| 1 | 5/25(20) |
| 2 | 2/25 (8) |
| Synchronous metastatic disease | 10/25 (40) |
| Bone met | 3/25 (12) |
| Liver met | 7/25 (25) |
| Lung | 8/25 (32) |
| Nodes | 20/25 (80) |
IMDC (International Metastatic RCC Database Consortium); ECOG PS (Eastern Cooperative Oncology Group Performance Status)
Conclusions
Pembrolizumab-axitinib could be an active option in papillary and cromophobe RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Meet-URO: Italian Network For Research In Urologic-Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.